HER-096
Herantis takes the final step towards a clinic with an issuance
Parkinson's is today the world's second most common neurodegenerative disease. Much is still unknown about the origin of the disease and there are...
BioStock Studio: Herantis Pharma on the issue
Finnish Herantis Pharma is developing its candidate HER-096 against...
Intervju
Video
Herantis' acting CEO on the issue and the path to the clinic
Parkinson's is a severe neurodegenerative disease in which...
Intervju
BioStock Investor Pitch: Herantis Pharma
Finnish Herantis Pharma, listed in both Finland and...
Video